Zoetis Inc (NYSE:ZTS) insider Heidi C. Chen sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $93.51, for a total value of $233,775.00. Following the completion of the sale, the insider now owns 17,662 shares in the company, valued at approximately $1,651,573.62. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of NYSE:ZTS opened at $88.09 on Friday. The firm has a market cap of $43.51 billion, a price-to-earnings ratio of 36.70, a P/E/G ratio of 1.79 and a beta of 0.99. The company has a debt-to-equity ratio of 3.04, a quick ratio of 2.63 and a current ratio of 4.06. Zoetis Inc has a one year low of $70.20 and a one year high of $96.57.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, November 1st. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The firm had revenue of $1.48 billion for the quarter, compared to analysts’ expectations of $1.46 billion. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. Zoetis’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.65 EPS. As a group, equities research analysts forecast that Zoetis Inc will post 3.11 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th were issued a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend was Monday, November 19th. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.

A number of large investors have recently made changes to their positions in the business. Rehmann Capital Advisory Group lifted its stake in shares of Zoetis by 9.7% during the 3rd quarter. Rehmann Capital Advisory Group now owns 2,403 shares of the company’s stock worth $220,000 after purchasing an additional 213 shares during the period. Marshall Wace North America L.P. lifted its stake in shares of Zoetis by 32.6% during the 3rd quarter. Marshall Wace North America L.P. now owns 4,202,241 shares of the company’s stock worth $384,757,000 after purchasing an additional 1,034,161 shares during the period. Marshall Wace LLP lifted its stake in shares of Zoetis by 76.4% during the 3rd quarter. Marshall Wace LLP now owns 3,216,573 shares of the company’s stock worth $294,509,000 after purchasing an additional 1,393,397 shares during the period. MARSHALL WACE ASIA Ltd purchased a new position in shares of Zoetis during the 3rd quarter worth $9,773,000. Finally, Great Lakes Advisors LLC lifted its stake in shares of Zoetis by 201.5% during the 3rd quarter. Great Lakes Advisors LLC now owns 48,635 shares of the company’s stock worth $4,453,000 after purchasing an additional 32,502 shares during the period. Hedge funds and other institutional investors own 89.94% of the company’s stock.

A number of research firms recently weighed in on ZTS. Argus set a $105.00 price target on Zoetis and gave the stock a “buy” rating in a report on Tuesday, November 13th. BMO Capital Markets upped their price target on Zoetis to $93.00 and gave the stock a “neutral” rating in a report on Monday, November 12th. They noted that the move was a valuation call. JPMorgan Chase & Co. increased their target price on Zoetis from $100.00 to $101.00 and gave the company an “overweight” rating in a report on Friday, November 2nd. Morgan Stanley set a $100.00 target price on Zoetis and gave the company a “hold” rating in a report on Friday, November 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $105.00 target price (up previously from $98.00) on shares of Zoetis in a report on Wednesday, October 17th. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Zoetis presently has a consensus rating of “Buy” and a consensus target price of $94.00.

WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2018/12/08/heidi-c-chen-sells-2500-shares-of-zoetis-inc-zts-stock.html.

About Zoetis

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Featured Story: What is Depreciation?

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.